+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Circulating matrix metalloproteinase-9 is transiently elevated after colorectal surgery



Circulating matrix metalloproteinase-9 is transiently elevated after colorectal surgery



International Journal of Colorectal Disease 19(5): 446-450



Plasma levels of matrix metalloproteinases (MMPs) may yield important information in patients suffering from colorectal cancer but the effect of surgery, a common treatment modality in these patients, on circulating MMP levels is currently unknown. The aim of this study was to assess whether plasma MMP-2 and MMP-9 levels are affected by operative procedures. In total 128 patients undergoing elective surgery for colorectal cancer (n = 66), liver metastases from colorectal origin (n = 50) and arthrosis of the hip (n = 12) were included in the study. Gelatinase activity was measured, using quantitative gelatin zymography, in plasma obtained before operation and 1 week, 1 month and 3 months postoperatively. One week after operation a significant increase in proMMP-9 activity was measured after colorectal surgery (260%, p = 0.0038), liver surgery (285%, p < 0.0001) and hip surgery (217%, p = 0.012) as compared with preoperative levels. After 1 month proMMP-9 activity had returned to preoperative levels. No effect on proMMP-2 activity was measured. Operative procedures have a profound but transient effect on plasma MMP-9 activity. If used to assess disease status, postoperative plasma MMP levels should be interpreted with caution.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011861471

Download citation: RISBibTeXText

PMID: 14986032

DOI: 10.1007/s00384-004-0578-4


Related references

Circulating levels of Matrix metalloproteinase-9 and Matrix metalloproteinase-2 in patients with colorectal cancer. Clinical Chemistry & Laboratory Medicine 37(SPEC SUPPL ): S237, June, 1999

Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. American Heart Journal 150(3): 484-487, 2005

Minimally invasive colorectal resection is associated with significantly elevated levels of plasma matrix metalloproteinase 3 (MMP-3) during the first month after surgery which may promote the growth of residual metastases. Surgical Endoscopy 28(12): 3322-3328, 2015

Elevated circulating matrix metalloproteinase-2 in coronary heart disease. European Heart Journal 19(ABST SUPPL ): 613, 1998

Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. European Journal of Heart Failure 6(1): 41-45, 2004

Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respiratory Medicine 95(1): 1-4, 2001

Circulating levels of matrix metalloproteinase-9 in patients with colorectal cancer. Scandinavian Journal of Gastroenterology 35(6): 671-672, 2000

Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clinica Chimica Acta; International Journal of Clinical Chemistry 367(1-2): 103-107, 2006

Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Internal Medicine Journal 35(6): 331-335, 2005

Re: Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer (Respir Med 2001; 95: 1-4). Respiratory Medicine 96(2): 126-129, 2002

Elevated levels of circulating matrix metalloproteinase-9 in non-small cell lung cancer patients. Tuberkuloz Ve Toraks 51(4): 380-384, 2004

Elevated levels of matrix metalloproteinase-9 correlate with metastases in human colorectal cancer. Proceedings of the American Association for Cancer Research Annual Meeting 35(0): 87, 1994

Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clinical Cancer Research 5(1): 149-153, 1999

Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration. Molecular Vision 19: 729-736, 2013